News
Vertex shares additional updates on zimislecel in type 1 diabetes
Vertex Pharmaceuticals shared an additional look at data from the Phase 1/2 FORWARD clinical trial, investigating the use of zimislecel for the treatment of type 1 diabetes complicated by severe hypog...
Orforglipron taken orally once daily leads to significant body weight loss
New research presented at the Annual Meeting of the European Association for the Study of Diabetes 2025 shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substan...
Roche receives CE mark for Accu-Chek SmartGuide continuous glucose monitoring and mySugr app integration
Roche shared real-world evidence from the rollout of Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution at the European Association for the Study of Diabetes (EASD), and announced its i...
Semaglutide provides powerful protection against diabetic retinopathy, study suggests
GLP-1 receptor agonist drugs protect against diabetic retinopathy – a common complication of diabetes that can lead to sight loss. This research was presented at the annual meeting of the European Ass...
Type 2 diabetes may double risk of sepsis, study suggests
Living with type 2 diabetes may double the risk of developing sepsis, especially those aged younger than 60 years and men, according to a long-term community-based study in Australia. This research wa...
Gestational diabetes linked to cognitive decline in mothers and neurodevelopmental disorders among children
A new synthesis of global evidence finds that experiencing gestational diabetes during pregnancy is linked with a decline in intellectual function among mothers, and may increase the risk of autism sp...
Tirzepatide helps weight loss among people with type 1 diabetes, research shows
In adults with type 1 diabetes and obesity, low dose tirzepatide reduced their weight, HbA1c levels and insulin dose requirements, a clinical trial has demonstrated. Presented at this year’s EASD meet...
Researchers urged to warn about women with type 2 diabetes taking oral HRT
In women with type 2 diabetes, use of hormone replacement therapy (HRT) skin patches is not associated with a higher risk of blood clots or stroke. However, an increased cardiovascular risk was found ...
Spirit Health launches CareSens Air CGM giveaway for World Diabetes Day
As part of its ongoing commitment to improving access to innovative diabetes technology, Spirit Health has announced a CareSens Air Continuous Glucose Monitor (CGM) giveaway for healthcare professiona...